| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
L-Arginine targets nitric oxide synthase (NOS) and is a substrate for the production of nitric oxide (NO), a key signaling molecule involved in vasodilation and immune function. Arginine also plays important roles in cell division, wound healing, ammonia removal from the body, immune function, and hormone release. The labeled compound is used to study arginine metabolism.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, L-arginine stimulates NO production in endothelial cells and macrophages via NOS activation. The labeled compound is used to trace arginine uptake and metabolism in cell culture. Arginine promotes cell proliferation and wound healing in vitro. The compound's activity is assessed by measuring nitrite/nitrate accumulation (Griess assay) or by quantifying labeled metabolites by LC-MS/MS. |
| ln Vivo |
In vivo, L-arginine acts as a vasodilator by increasing NO production, thereby reducing blood pressure. It is involved in the urea cycle for ammonia detoxification. The 13C and 15N labeled form is used in metabolic flux studies to trace arginine metabolism and protein synthesis in animal models. It is essential for studying arginine-related metabolic disorders and nitrogen balance.
|
| Enzyme Assay |
In vitro enzyme assays for NOS involve incubating the enzyme with L-Arginine-13C6,15N4 hydrochloride, NADPH, tetrahydrobiopterin (BH4), and oxygen in HEPES buffer at pH 7.4. NO production is measured by the conversion of oxyhemoglobin to methemoglobin or by the Griess reaction for nitrite. The labeled substrate allows for precise quantification of citrulline production by LC-MS/MS. Kinetic parameters are determined by varying substrate concentrations.
|
| Cell Assay |
For in vitro cell assays, endothelial cells or macrophages are cultured in arginine-free medium supplemented with L-Arginine-13C6,15N4 hydrochloride at concentrations of 0.1-10 mM. NO production is measured by the Griess assay. Cellular uptake and metabolism of labeled arginine are analyzed by LC-MS/MS. Cell proliferation is assessed by MTT assay. The compound's effects on NOS activity and downstream signaling pathways are evaluated by Western blot and qPCR.
|
| Animal Protocol |
For in vivo animal studies, L-Arginine-13C6,15N4 hydrochloride is administered to rodents via oral gavage or intravenous injection at doses of 100-500 mg/kg. Blood samples are collected at various time points for pharmacokinetic analysis. Plasma arginine and citrulline levels are quantified by LC-MS/MS. Metabolic flux analysis traces the incorporation of 13C and 15N into downstream metabolites such as NO, citrulline, ornithine, and polyamines. Tissue distribution studies are performed to assess arginine utilization.
|
| ADME/Pharmacokinetics |
L-Arginine-13C6,15N4 hydrochloride has a molecular weight of 220.59. It is soluble in water and physiological buffers. The compound is stable as a powder at -20°C for 3 years and in solvent at -80°C for 1 year. The 13C and 15N labeling provides a mass shift of +10 Da for MS detection. It is absorbed via amino acid transporters and metabolized through the arginase and NOS pathways.
|
| Toxicity/Toxicokinetics |
L-Arginine is generally recognized as safe at physiological concentrations. The labeled form is not expected to exhibit additional toxicity. High doses may cause gastrointestinal disturbances. The compound is for research use only, not for human therapeutic applications. No specific toxicity data are available for the labeled analog; safety profiles are extrapolated from L-arginine, which is an endogenous amino acid.
|
| References | |
| Additional Infomation |
L-Arginine-13C6,15N4 hydrochloride (CAS# 202468-25-5) is a stable isotope-labeled compound used primarily as a tracer in metabolic studies and protein quantification. It has not been investigated in clinical trials nor approved as a therapeutic drug. The compound is widely used in research on nitric oxide biology, urea cycle disorders, and amino acid metabolism. The isotopically labeled form enables precise tracking of arginine metabolism in complex biological systems.
|
| Molecular Formula |
13C6H15CL15N4O2
|
|---|---|
| Molecular Weight |
220.59
|
| Exact Mass |
220.096
|
| CAS # |
202468-25-5
|
| Related CAS # |
L-Arginine hydrochloride;1119-34-2
|
| PubChem CID |
71310244
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
13
|
| Complexity |
176
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[13CH2]([13CH2][13C@@H]([13C](=O)O)[15NH2])[13CH2][15N]=[13C]([15NH2])[15NH2].Cl
|
| InChi Key |
KWTQSFXGGICVPE-YAUSPDTOSA-N
|
| InChi Code |
InChI=1S/C6H14N4O2.ClH/c7-4(5(11)12)2-1-3-10-6(8)9;/h4H,1-3,7H2,(H,11,12)(H4,8,9,10);1H/t4-;/m0./s1/i1+1,2+1,3+1,4+1,5+1,6+1,7+1,8+1,9+1,10+1;
|
| Chemical Name |
(2S)-2-(15N)azanyl-5-[bis(15N)(azanyl)(113C)methylideneamino](1,2,3,4,5-13C5)pentanoic acid;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 125 mg/mL (566.66 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5333 mL | 22.6665 mL | 45.3330 mL | |
| 5 mM | 0.9067 mL | 4.5333 mL | 9.0666 mL | |
| 10 mM | 0.4533 mL | 2.2666 mL | 4.5333 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
